Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

May 1, 2017

Study Completion Date

May 1, 2017

Conditions

Diabetes Type IDiabetes Type II

Interventions

BIOLOGICAL

DermGEN

DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.

Trial Locations (2)

Queen Elizabeth II Health Sciences Center, Halifax

St. Michael's Hospital, Toronto

All Listed Sponsors

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Nova Scotia Health Authority

OTHER

lead

Dr. Paul F. Gratzer

INDUSTRY

NCT02184455 - Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment | Biotech Hunter | Biotech Hunter